Mirivadelgat

Mirivadelgat
Identifiers
	IUPAC name [2-[4-(cyclopropylmethoxy)-3-[(3-fluoro-4-methoxyphenyl)methylcarbamoyl]phenyl]-3-pyridinyl]methyl (2S)-2-amino-3-methylbutanoate;
CAS Number	1804941-96-5;
PubChem CID	126646947;
ChemSpider	133327633;
UNII	22TB7Q431D;
Chemical and physical data
Formula	C30H34FN3O5
Molar mass	535.616 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)OCC1=C(N=CC=C1)C2=CC(=C(C=C2)OCC3CC3)C(=O)NCC4=CC(=C(C=C4)OC)F)N;
	InChI InChI=InChI=1S/C30H34FN3O5/c1-18(2)27(32)30(36)39-17-22-5-4-12-33-28(22)21-9-11-25(38-16-19-6-7-19)23(14-21)29(35)34-15-20-8-10-26(37-3)24(31)13-20/h4-5,8-14,18-19,27H,6-7,15-17,32H2,1-3H3,(H,34,35)/t27-/m0/s1; Key:ONYMVJFFLSQCKA-MHZLTWQESA-N;

Mirivadelgat is an investigational new drug that is being evaluated by Foresee Pharmaceuticals for the treatment of pulmonary arterial hypertension.^[1] It is an aldehyde dehydrogenase 2 activator.^[1]^[2]

References

1 2 "Mirivadelgat". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ Grubwieser P, Bonkat N, Sailer B, Schroll A, Löffler-Ragg J, Weiss G, et al. (April 2026). "Emerging treatments in pulmonary arterial hypertension: a current review". European Journal of Medical Research. 31 887. doi:10.1186/s40001-026-04515-5.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.